SuperworthCollegium Pharmaceutical profit margin COLL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- 5.9%
- Operating margin, 12 months
- 19.5%
- Net margin on a year earlier
- +0.8 pts
- Peer median
- 22.5%
Over the twelve months to Jun 30, 2026, Collegium Pharmaceutical kept 5.9% of its revenue as net profit, with an operating margin of 19.5% and a gross margin of 60.0%.
Five years earlier its net margin was 32.7%.
The median for 10 large drugmakers of a similar size is 22.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.1% | 23.0% | 59.3% |
| FY2024 | 11.0% | 26.9% | 59.8% |
| FY2023 | 8.5% | 29.5% | 57.5% |
| FY2022 | −5.4% | 7.2% | 45.2% |
| FY2021 | 25.8% | 6.4% | 54.4% |
| FY2020 | 8.6% | 18.1% | 58.0% |
| FY2019 | −7.7% | −8.0% | 34.7% |
| FY2018 | −14.0% | −7.4% | 40.9% |
| FY2017 | n/a | n/a | 90.9% |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 5.9% | +0.8 pts | 19.5% | |
| Q1 FY26 | 9.4% | +2.8 pts | 23.7% | |
| Q4 FY25 | 8.1% | −2.9 pts | 23.0% | |
| Q3 FY25 | 7.7% | −7.1 pts | 20.7% | |
| Q2 FY25 | 5.1% | −12.2 pts | 18.4% | |
| Q1 FY25 | 6.6% | −9.8 pts | 21.4% | |
| Q4 FY24 | 11.0% | +2.5 pts | 26.9% | |
| Q3 FY24 | 14.8% | +13.1 pts | 32.3% | |
| Q2 FY24 | 17.3% | +19.4 pts | 35.3% | |
| Q1 FY24 | 16.5% | +22.0 pts | 33.8% | |
| Q4 FY23 | 8.5% | +13.9 pts | 29.5% | |
| Q3 FY23 | 1.6% | +13.5 pts | 21.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Collegium Pharmaceutical's size, closest first, today.
| Company | Profit margin |
|---|---|
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| PBYIPuma Biotechnology | 11.6% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| ARVNArvinas | 2.9% |
| OMEROmeros | n/m |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| Peer median | 22.5% |
Where Collegium Pharmaceutical ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Collegium Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.